Why is Zimmer Biomet stock climbing today?
Zimmer Biomet stock rose 1.8% in morning trading as a wave of bullish analyst activity — headlined by a Wells Fargo upgrade to Overweight with a raised price target of $123 — gave investors fresh conviction in the orthopedic device maker’s near-term growth story. Wells Fargo analyst Larry Biegelsen issued the upgrade today, arguing that the upcoming Monogram robotic system launch directly addresses the one soft spot in Zimmer Biomet’s otherwise mid-single-digit-growing portfolio: its knee segment, which accounts for roughly 38% of sales and is expected to decline modestly in 2026.
Adding further momentum, Stifel raised its price target on the stock to $140 from $125 while reiterating a Buy rating, after high-volume orthopedic surgeons at a healthcare conference expressed enthusiasm for Monogram’s capacity to improve patient outcomes and reduce surgeon physical strain through automated bone-cutting. Truist Securities also lifted its target to $114. Partially tempering the enthusiasm, BMO Capital trimmed its target by $1 to $101, maintaining a Market Perform rating on concerns that a dual-currency $1 billion senior notes offering announced last week will add meaningfully to the company’s annual interest expense.
The stock’s advance comes against a challenging macro backdrop: the S&P 500, Dow Jones, and Nasdaq all fell roughly 1.0%–1.4% during today’s session, making ZBH’s gain a clear display of stock-specific strength. The broader medtech and healthcare sector faced similar headwinds, yet Zimmer Biomet managed to trade well above its opening price of $102.12, reaching an intraday high of $104.28.
Taken together, the convergence of multiple upward analyst revisions — anchored by Wells Fargo’s outright upgrade and Stifel’s aggressive $140 target — centered on the Monogram robotics timeline proved sufficient to lift shares even as macro conditions weighed on the broader market, reinforcing the view that the stock’s robotics-driven re-rating story remains intact.